IO Biotech will deliver a late-breaking oral presentation at ESMO 2025 with primary results from its randomized phase 3 trial of Cylembio, an off-the-shelf IDO1/PD-L1-targeted cancer vaccine, combined with pembrolizumab versus pembrolizumab alone in first-line advanced melanoma. The company will also present final data from a phase 2 basket study of the same regimen in first-line non-small cell lung cancer and head and neck cancer. The pivotal melanoma study enrolled 407 patients, used progression-free survival as its primary endpoint, and completed enrollment in December 2023; topline results were reported in the third quarter, with full data reserved for ESMO’s proffered paper session.
The ESMO platform raises the stakes. Late-breaking, proffered slots usually signal data with potential to move clinical practice, whether by validating a new standard or drawing a clear boundary around what does not work. For Commercial and Medical Affairs leaders, the strategic question is straightforward: does an immune-modulatory vaccine meaningfully shift the PD-1 backbone in melanoma, a space shaped recently by PD-1 plus LAG-3 and historically by PD-1 plus CTLA-4, and can it do so with a safety and cost profile that resonates with payers?
If the Cylembio combination demonstrates a clinically relevant PFS advantage with manageable toxicity, it could open a new chapter for therapeutic cancer vaccines after years of skepticism following IDO pathway disappointments. Mechanistically, this approach differs from small-molecule IDO inhibition by training T cells against IDO1- and PD-L1-expressing cells in the tumor microenvironment, aiming to debulk immune suppression rather than inhibit an enzyme. For patients, the promise is additive efficacy without the immune-related toxicity seen with some dual-checkpoint strategies. For oncologists, an off-the-shelf regimen layered onto familiar pembrolizumab schedules could be operationally simple. For payers, the burden of proof will be magnitude and durability of benefit, especially since the trial’s primary endpoint is PFS rather than OS, a nuance that has mattered in melanoma approvals and HTA assessments across geographies.
The commercial implications are equally pointed. Melanoma first-line is crowded and increasingly defined by combination efficacy. Bristol Myers Squibb’s PD-1 plus LAG-3 has reset expectations on PFS. To displace or complement existing regimens, IO Biotech will need to show clear risk-benefit separation and a manufacturing and pricing model that undercuts more complex biologic combinations. As an off-the-shelf peptide vaccine, Cylembio could be cost-advantaged versus cellular approaches and more scalable than bespoke neoantigen platforms, but payer acceptance will hinge on comparative effectiveness and real-world tolerability. With Merck supplying pembrolizumab yet IO Biotech retaining global rights, strong results could catalyze broader partnership or co-commercialization moves, aligning with big pharma’s strategy to defend PD-1 market share through differentiated add-ons as loss of exclusivity approaches.
For Medical Affairs, the immediate tasks are biomarker strategy, regimen education, and RWE planning. Exploratory tumor and blood biomarkers, including IDO1 and PD-L1 expression, could refine patient selection and support payer negotiations. Implementation details matter: scheduling, injection-site management, and vigilance for immune-mediated events in combination settings will shape prescriber confidence. The phase 2 basket data in lung and head and neck cancers will indicate whether the biology travels across tumor types, informing trial prioritization in adjuvant and neoadjuvant settings where vaccines may be most potent.
The broader trend is unmistakable: from mRNA neoantigens to peptide platforms, therapeutic vaccination is re-entering mainstream oncology through PD-1-enabled combinations. ESMO will show whether IO Biotech’s approach can convert that momentum into first-line relevance. The next competitive question is whether the data are strong enough to challenge the PD-1 plus LAG-3 benchmark—and, if so, whether regulators and payers will accept PFS as the foundation for a new standard of care.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
